Picture loading failed.

Pre-Made Ongericimab biosimilar, Whole mAb, Anti-PCSK9 Antibody: Anti-FH3/FHCL3/HCHOLA3/LDLCQ1/NARC-1/NARC1/PC9 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ongericimab (formerly JS 002) is a recombinant humanised anti-PCSK9 monoclonal antibody, for subcutaneous injection, being developed by Shanghai Junshi.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-403-1mg 1mg 3090
GMP-Bios-ab-403-10mg 10mg Inquiry
GMP-Bios-ab-403-100mg 100mg Inquiry
GMP-Bios-ab-403-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Ongericimab biosimilar, Whole mAb, Anti-PCSK9 Antibody: Anti-FH3/FHCL3/HCHOLA3/LDLCQ1/NARC-1/NARC1/PC9 therapeutic antibody
INN Name Ongericimab
TargetPCSK9
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesShanghai Junshi Biosciences
Conditions Approvedna
Conditions ActiveHypercholesterolemia
Conditions Discontinuedna
Development Techna